Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Living with Advanced Kidney Cancer and Treatment with Cabozantinib: Through the Eyes of the Patient and the Physician

Living with Advanced Kidney Cancer and Treatment with Cabozantinib: Through the Eyes of the... This article is co-authored by a patient with advanced renal cell carcinoma and his treating oncologist. The patient relates his personal experiences in struggling with cancer, including physical limitations, but also details his psychological, existential and spiritual distress through the cancer journey. The patient shares a proactive approach to the most common side effects of therapy. The professional reflects on the rapid development of new therapy options; the implications for clinical practice by the management of long-tem therapy; how to deal with patient expectations; and the management of patient distress as an integrated part of the contemporary approach for treating kidney cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Living with Advanced Kidney Cancer and Treatment with Cabozantinib: Through the Eyes of the Patient and the Physician

Storbjerg, Bent; Donskov, Frede
Oncology and Therapy , Volume 6 (1) – Mar 22, 2018
Download PDF
7 pages

Loading next page...
 
/lp/springer-journals/living-with-advanced-kidney-cancer-and-treatment-with-cabozantinib-j2AmeQWtMt
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-018-0057-7
Publisher site
See Article on Publisher Site

Abstract

This article is co-authored by a patient with advanced renal cell carcinoma and his treating oncologist. The patient relates his personal experiences in struggling with cancer, including physical limitations, but also details his psychological, existential and spiritual distress through the cancer journey. The patient shares a proactive approach to the most common side effects of therapy. The professional reflects on the rapid development of new therapy options; the implications for clinical practice by the management of long-tem therapy; how to deal with patient expectations; and the management of patient distress as an integrated part of the contemporary approach for treating kidney cancer.

Journal

Oncology and Therapy – Springer Journals

Published: Mar 22, 2018

References

  • From birth to one
    Robinson, M
  • Radical nephrectomy for renal cell carcinoma
    Robson, CJ
  • Trends in the survival of patients diagnosed with kidney or urinary bladder cancer in the Nordic countries 1964–2003 followed up to the end of 2006
    Engholm, G; Hakulinen, T; Gislum, M; Tryggvadóttir, L; Klint, A; Bray, F
  • Computerized transverse axial tomography
    Ambrose, J; Hounsfield, G
  • Cancer statistics, 2017
    Siegel, RL; Miller, KD; Jemal, A
  • Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
    Yang, JC; Hughes, M; Kammula, U; Royal, R; Sherry, RM; Topalian, SL
  • Systemic therapy for metastatic renal-cell carcinoma
    Choueiri, TK; Motzer, RJ
  • Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
    Zhou, L; Liu, X-D; Sun, M; Zhang, X; German, P; Bai, S
  • A phase I study of cabozantinib (XL184) in patients with renal cell cancer
    Choueiri, TK; Pal, SK; McDermott, DF; Morrissey, S; Ferguson, KC; Holland, J
  • Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
    Motzer, RJ; Hutson, TE; Glen, H; Michaelson, MD; Molina, A; Eisen, T
  • Treatment of renal cell carcinoma: Current status and future directions
    Barata, PC; Rini, BI
  • Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma
    Motzer, RJ; Haas, NB; Donskov, F; Gross-Goupil, M; Varlamov, S; Kopyltsov, E
  • Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma
    Motzer, RJ; Mazumdar, M; Bacik, J; Berg, W; Amsterdam, A; Ferrara, J
  • Local treatments for metastases of renal cell carcinoma: a systematic review
    Dabestani, S; Marconi, L; Hofmann, F; Stewart, F; Lam, TBL; Canfield, SE
  • Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2
    Soerensen, AV; Donskov, F; Hermann, GG; Jensen, NV; Petersen, A; Spliid, H
  • Third-line targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium
    Wells, JC; Stukalin, I; Norton, C; Srinivas, S; Lee, JL; Donskov, F
  • Distress management
    Holland, JC; Andersen, B; Breitbart, WS; Buchmann, LO; Compas, B; Deshields, TL